Idorsia Ltd/€IDIA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Idorsia Ltd
Idorsia Ltd is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company focuses on the discovery, development, and commercialization of innovative medicines. Idorsia’s pipeline includes treatments for a variety of conditions, with a particular emphasis on central nervous system disorders, cardiovascular diseases, and rare diseases. Notably, it was founded in June 2017 as a spinoff from Actelion, following its acquisition by Johnson & Johnson. Idorsia leverages its deep scientific expertise to progress its drug candidates from early-stage research through clinical development, aiming to address significant unmet medical needs. Sources:
- Company Website
- Publicly available financial and corporate reports
Ticker
€IDIA
Sector
Primary listing
XGAT
Employees
650
Headquarters
Allschwil, Switzerland
Website
Idorsia Ltd Metrics
BasicAdvanced
€1.1B
-
-€0.76
1.51
-
Price and volume
Market cap
€1.1B
Beta
1.51
52-week high
€5.33
52-week low
€0.65
Average daily volume
17K
Financial strength
Current ratio
0.725
Quick ratio
0.444
Long term debt to equity
-95.643
Total debt to equity
-114.165
Interest coverage (TTM)
-27.07%
Profitability
EBITDA (TTM)
-165.472
Gross margin (TTM)
26.22%
Net profit margin (TTM)
-61.37%
Operating margin (TTM)
-79.66%
Effective tax rate (TTM)
-3.20%
Revenue per employee (TTM)
€354,620
Management effectiveness
Return on assets (TTM)
-18.52%
Return on equity (TTM)
12.21%
Valuation
Price to revenue (TTM)
4.078
Price to book
-0.84
Price to tangible book (TTM)
-0.82
Price to free cash flow (TTM)
-3.374
Free cash flow yield (TTM)
-29.64%
Free cash flow per share (TTM)
-1.48
Growth
Revenue change (TTM)
69.92%
Earnings per share change (TTM)
-540.86%
3-year revenue growth (CAGR)
70.56%
3-year earnings per share growth (CAGR)
-46.71%
Bulls say / Bears say
Securing a CHF 150 million new-money facility extends Idorsia’s cash runway into mid-2026, significantly reducing liquidity risk and allowing management to focus on commercial execution (Bloomberg Law).
Reported net income of CHF 52 million on revenue of CHF 131 million for H1 2025, extending the cash runway to the end of 2026 and setting the company on track for commercial profitability in 2026 (Reuters).
With the implementation of the CHF 150 million facility, management upgraded its 2025 guidance, indicating confidence in stronger revenue growth and a reduction in losses going forward (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Idorsia Ltd stock?
Idorsia Ltd (IDIA) has a market cap of €1.1B as of October 08, 2025.
What is the P/E ratio for Idorsia Ltd stock?
The price to earnings (P/E) ratio for Idorsia Ltd (IDIA) stock is 0 as of October 08, 2025.
Does Idorsia Ltd stock pay dividends?
No, Idorsia Ltd (IDIA) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Idorsia Ltd dividend payment date?
Idorsia Ltd (IDIA) stock does not pay dividends to its shareholders.
What is the beta indicator for Idorsia Ltd?
Idorsia Ltd (IDIA) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.